Melanotan-1: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข3 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 40 community reports
- โข2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| MC Receptor Selectivity | Melanotan-1 (afamelanotide) is a linear alpha-MSH analog with higher selectivity for MC1R (melanogenesis) compared to Melanotan-2. This selectivity reduces off-target effects on MC4R (sexual function, appetite). Approved as Scenesse for erythropoietic protoporphyria. | Community users choose MT-1 over MT-2 specifically to avoid libido and appetite side effects while still achieving tanning. Higher doses are needed per mg compared to MT-2 due to the more selective receptor profile. | moderate MT-1 selectivity for MC1R means less off-target effects but also less potent tanning per mg, requiring higher doses and potentially higher cost. |
| Regulatory Status | Afamelanotide is approved in Europe and the US (as Scenesse) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The approved formulation is a 16 mg subcutaneous implant administered every 2 months. | Community use of MT-1 is for cosmetic tanning, distinct from the approved EPP indication. Community users inject reconstituted peptide subcutaneously rather than using the implant formulation. | high While afamelanotide (MT-1) has regulatory approval for EPP, community cosmetic tanning use is off-label and uses a different formulation. |
| Dosing Scale | The approved Scenesse implant delivers 16 mg over approximately 2 months. Clinical tanning studies used various doses. | Community doses are 0.5-1.0 mg daily during loading, substantially lower daily exposure than the sustained-release implant provides. | moderate Community dosing produces lower daily exposure than the approved implant, which may result in less consistent pigmentation effects. |
Compare these community approaches with published research findings.
Community Protocols
Standard Loading Protocol
Popular- Route
- Subcutaneous
- Dose
- 0.5-1.0 mg
- Frequency
- Once daily
- Duration
- 10 days (loading), then maintenance
Higher doses than MT-2 due to MC1R selectivity (less potent per mg); combined with moderate UV exposure
Maintenance Protocol
Common- Route
- Subcutaneous
- Dose
- 1.0-2.0 mg
- Frequency
- Once weekly
- Duration
- Ongoing (during sun season)
After initial loading; approximately 8 mg per month for maintenance
Conservative Protocol
Common- Route
- Subcutaneous
- Dose
- 0.5 mg
- Frequency
- Once daily
- Duration
- 2-3 weeks then biweekly
Lower dose for gradual tanning with minimal side effects; preferred by those sensitive to nausea
Stacking Patterns
MT-1 Tanning Protocol
CommonStandalone MT-1 for tanning without the off-target sexual function and appetite effects of MT-2; preferred by users wanting pure tanning effects
MT-1 vs MT-2 Selection
CommonCommunity members choose between MT-1 and MT-2 based on desired side effect profile; MT-1 for cleaner tanning, MT-2 for additional libido and appetite suppression effects
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 40+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|Melanotan-1 vs Melanotan-2 comparison and protocol discussions(accessed 2026-02-16)
- Peptides.org|Melanotan 1 Dosage Calculator and Chart(accessed 2026-02-16)
- Real Peptides|How We Dose Melanotan 1: The Researcher Protocol(accessed 2026-02-16)
- Pep-pedia|Melanotan-1 overview and community information(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Melanotan-1 (MT-1/Afamelanotide). The information below is gathered from peptide forums, tanning communities, and Reddit. This is not clinical evidence and should not be used as medical guidance.
Melanotan-1 has a smaller but growing community user base compared to Melanotan-2. Its primary appeal is the more selective MC1R activation profile, which produces tanning effects with fewer off-target side effects. The existence of an FDA-approved formulation (Scenesse for EPP) provides some additional pharmacological validation, though community use for cosmetic tanning is distinctly different from the approved indication.
Understanding Protocol Divergence#
MT-1 vs MT-2 Selection#
The community views MT-1 and MT-2 as complementary options rather than direct alternatives. MT-1 is chosen by users who want tanning without libido changes, appetite suppression, or the more pronounced nausea associated with MT-2. MT-2 is preferred by those who welcome the off-target effects or want stronger tanning per mg at lower cost.
Dose Requirements#
MT-1 requires higher per-mg dosing than MT-2 due to its more selective receptor profile. This translates to higher cost per tanning cycle and is an important practical consideration for community users choosing between the two melanotans.
Commonly Reported Outcomes#
- Gradual tanning: Slower onset than MT-2 but more natural-looking pigmentation development
- Fewer side effects: Less nausea, minimal libido changes, reduced appetite effects compared to MT-2
- Mole darkening: Still reported, though potentially less pronounced than with MT-2
- Onset timeline: Early signs within 1-2 weeks, significant tanning by weeks 3-5 with UV exposure
- Plateau: Tanning typically plateaus at 6-8 weeks
Important Caveats#
- Community cosmetic tanning use is off-label despite Scenesse approval for EPP
- Mole monitoring remains important with MT-1
- Higher cost per cycle compared to MT-2
- UV exposure combination creates additional skin risk
- Long-term safety of repeated MT-1 cycles for cosmetic use is not established
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Melanotan-1
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.